These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38993547)

  • 1. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma.
    Yang Z; Cheung RC; Jou JH; Lim JK; Lim YS; Wong RJ
    Gastroenterology Res; 2024 Jun; 17(3):109-115. PubMed ID: 38993547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B.
    Yang Z; Cheung RC; Chitnis AS; Zhang W; Gish RG; Wong RJ
    JHEP Rep; 2023 Oct; 5(10):100852. PubMed ID: 37701335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
    J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
    Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Han S; Lim YS
    J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
    Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
    J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Clark LJ; Jafry Z; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    Clin Gastroenterol Hepatol; 2024 Aug; ():. PubMed ID: 39181430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
    Wong RJ; Jain MK; Therapondos G; Niu B; Kshirsagar O; Thamer M
    Am J Gastroenterol; 2021 Jul; 116(7):1465-1475. PubMed ID: 33661148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.
    Kruse RL; Kramer JR; Tyson GL; Duan Z; Chen L; El-Serag HB; Kanwal F
    Hepatology; 2014 Dec; 60(6):1871-8. PubMed ID: 25065513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
    Li J; Dong XQ; Cao LH; Zhang ZQ; Zhao WF; Shang QH; Zhang DZ; Ma AL; Xie Q; Gui HL; Zhang G; Liu YX; Shang J; Xie SB; Liu YQ; Zhang C; Wang GQ; Zhao H;
    Front Cell Infect Microbiol; 2023; 13():1151899. PubMed ID: 37396307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis.
    Techathuvanan K; Srisajjakul S; Pongpaibul A; Limsrichamrern S; Charatcharoenwitthaya P; Chainuvati S; Tanwandee T; Chotiyaputta W
    J Med Assoc Thai; 2015 Apr; 98(4):334-42. PubMed ID: 25958707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso.
    Wongjarupong N; Yonli AT; Nagalo BM; Djigma FW; Somda SK; Hassan MA; Mohamed EA; Sorgho AP; Compaore TR; Soubeiga ST; Kiendrebeogo I; Sanou M; Diarra B; Yang HI; Chen CJ; Ouattara AK; Zohoncon TM; Martinson JJ; Buetow K; Chamcheu JC; Antwi SO; Borad MJ; Simpore J; Roberts LR
    Hepatol Commun; 2020 Dec; 4(12):1781-1792. PubMed ID: 33305149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis.
    Shin H; Choi WM; Kim SU; Ko Y; Park Y; Park J; Hur MH; Park MK; Lee YB; Kim YJ; Yoon JH; Lee JH; Zoulim F
    JHEP Rep; 2024 Jul; 6(7):101089. PubMed ID: 38974365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.